Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1

Active, not recruiting

Conditions: EGFR-mutant Non-small Cell Lung Cancer

Interventions: Drug: EGF816
Drug: trametinib
Drug: LXH254
Drug: ribociclib
Drug: gefitinib
Drug: INC280

First Posted Date: 2017-11-06

Last Posted Date: 2025-05-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT03333343

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Biological: Erenumab
Other: Placebo

First Posted Date: 2017-11-06

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 900

Registration Number: NCT03333109

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Omalizumab
Drug: Placebo

First Posted Date: 2017-11-01

Last Posted Date: 2020-11-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 418

Registration Number: NCT03328897

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: LIK066
Drug: Placebo

First Posted Date: 2017-10-25

Last Posted Date: 2024-06-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 126

Registration Number: NCT03320941

Locations: 🇯🇵
Novartis Investigative Site, Toshima-ku, Tokyo, Japan

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Everolimus Placebo

First Posted Date: 2017-10-18

Last Posted Date: 2024-01-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 159

Registration Number: NCT03312738

Locations: 🇨🇳
Novartis Investigative Site, Wuhan, China

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: LHC165
Biological: PDR001

First Posted Date: 2017-10-04

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03301896

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsatran
Drug: valsartan
Drug: placebo to valsartan
Drug: placebo to sacubitril/valsartan

First Posted Date: 2017-10-03

Last Posted Date: 2024-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT03300427

Locations: 🇫🇮
Novartis Investigative Site, Turku, Finland

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Other: Placebo to CJM112
Drug: CJM112

First Posted Date: 2017-10-03

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT03299686

Locations: 🇸🇰
Novartis Investigative Site, Spisska Nova Ves, Slovakia

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

Phase 2

Terminated

Conditions: Painful Diabetic Neuropathy

Interventions: Drug: EMA401
Drug: Placebo

First Posted Date: 2017-09-29

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT03297294

Locations: 🇬🇧
Novartis Investigative Site, Oldham, United Kingdom

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: VAY736
Drug: Standard of Care (SoC)

First Posted Date: 2017-09-19

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT03287414

Locations: 🇬🇧
Novartis Investigative Site, High Heaton, Newcastle Upon Tyne, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy